A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

NCT06649045 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

OSA
Overweight or Obesity

Interventions

DRUG: Orforglipron
DRUG: Placebo

Sponsor

Eli Lilly and Company